POST POLYCYTHEMIA VERA MYELOFIBROSIS

This study allows patients who are already taking the experimental drug bomedemstat for certain rare blood cancers to continue treatment in a long-term follow-up study. The main goal is to collect more information about the drug's safety and how well it continues to work over a l…

This is a first-in-human study to test the safety and find the right dose of an experimental oral drug called PRT12396 for people with certain rare blood cancers. It will enroll about 100 adults with high-risk polycythemia vera or myelofibrosis. The main goal is to see how well t…

This study is testing whether a drug called tasquinimod can help control myelofibrosis, a serious bone marrow cancer. It will be given either by itself or alongside an existing drug (ruxolitinib) to 33 adults whose current treatments aren't working well enough. The main goals are…

This early-stage trial is testing a new oral medication called AJ1-11095 for adults with myelofibrosis, a serious bone marrow cancer. The study is for patients whose disease didn't respond well to or came back after standard JAK2 inhibitor treatment. Researchers will determine th…

This study is testing an investigational drug called pacritinib against standard care treatments for adults with myelofibrosis, a serious bone marrow cancer, who also have dangerously low platelet counts. The main goals are to see if pacritinib can reduce spleen size and ease dis…

This study is creating a national patient registry in Germany to track how people with myelofibrosis (a bone marrow cancer) and anemia are treated in real-world clinics. It will follow 200 patients for up to three years to document which treatments they receive, in what order, an…

This is a long-term observational study designed to better understand a group of rare, chronic blood cancers called myeloproliferative neoplasms (MPNs). It will follow 5,000 adults in the U.S. for 5-10 years, collecting health records and patient surveys to track symptoms, treatm…